ReviewOncology reports2025
Advances in lymphoma biomarkers research based on proteomics technology (Review).
Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma is a common malignancy characterized by diverse pathological types and marked heterogeneity. Distinct subtypes of lymphomas are markedly different in their clinical manifestations, treatment approaches and prognostic outcomes. With the rapid development of molecular biology techniques, antitumor research has stepped into an era of precision medicine. Biomarkers, with high sensitivity and specificity, are expected to function in early diagnosis, targeted treatment and prognostic estimation for cancer and enhance the survival rate and life quality of patients. In this regard, proteomics technology, with the capability to systematically identify and quantify the dynamic protein alterations in tissues or cells, thereby facilitating the discovery of novel tumor potential candidates, has attracted significant scientific attention. The present article aimed to review most up‑to‑date research progress of lymphoma‑related biomarkers discovered based on proteomics technology, focusing on the potential application of these markers in the diagnosis, therapy and prognosis of each lymphoma subtype, and discuss the role proteomics may serve in future development of lymphoma research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.